Disease · MONDO_0800501

developmental and/or epileptic encephalopathy with spike-wave activation in sleep

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. developmental and/or epileptic encephalopathy with spike-wave activation in sleep. Diseases, record MONDO_0800501. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0800501

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: developmental and/or epileptic encephalopathy with spike-wave activation in sleep; Open Targets
Open Targets ID: MONDO_0800501; Open Targets
Other names: CSWS, CSWSS syndrome, DEE-SWAS, EE-SWAS, EESWAS, ESES with language regression, LK syndrome, LKS, continuous slow spike and wave of sleep, continuous spike-wave during slow sleep syndrome, continuous spike-wave in sleep, continuous spikes and waves during sleep, continuous spikes and waves during slow-wave sleep, developmental and epileptic encephalopathy with spike-wave activation in sleep, electrical status epilepticus of sleep, electrographic status epilepticus in sleep, electrographic status epilepticus of sleep, epileptic aphasia, epileptic encephalopathy with continuous spike-and-wave during slow sleep, epileptic encephalopathy with spike and wave activation in sleep, eses index; Open Targets
Orphanet: ORPHA:725; Orphanet
Highest stage of its drugs: Phase 2/3, for 2 of its 16 drugs, from ClinicalTrials.gov; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACETAZOLAMIDE	CHEMBL20	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
CLOBAZAM	CHEMBL70418	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Unknown	https://conductscience.org/library/genes/2908	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2/3	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02904265	Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome	Phase 2/3	3	2020-06-11	Landau-Kleffner Syndrome, Status Epilepticus, Electrographic	ACETAZOLAMIDE, DIAZEPAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT02127918	Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment		17		Electrical Status Epilepticus in Sleep	CLOBAZAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT04721691	Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).	Phase 1	16		Electrical Status Epilepticus of Slow-Wave Sleep	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT07221968	Melatonin for the Treatment of DEE-SWAS	Phase 2	3		CSWS, Developmental and/or Epileptic Encephalopathies, Electrical Status Epilepticus in Sleep	MELATONIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Diazepam vs Acetazolamide: Short-term Tolerability of Acetazolamide vs Diazepam	1 of 1	2 of 2	3	NCT02904265	Trial comparisons
Diazepam vs Acetazolamide: deaths from any cause	0 of 1	0 of 2	3	NCT02904265	Trial comparisons
Diazepam vs Acetazolamide: serious adverse events	0 of 1	0 of 2	3	NCT02904265	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0800501

GET https://conductscience.org/api/diseases/v1/MONDO_0800501/targets?page=2

API reference For AI assistants